Abstract

This presentation will describe the use of diet, Clofibrate, and one other drug on the treatment of different kinds of familial hyperlipidemia. The latter disorders were classified as different types of hyperlipoproteinemia (1). The use of such grouping of patients has many distinct advantages. Probably these are greatest in pharmacologic or dietary experiments and the extension of the results to practical management of affected patients. This has been demonstrated in the systematic trial of Clofibrate (CPIB, Atromid-S®) on each of the five major types of familial hyperlipoproteinemia. The companion effects of drug and diet have also been carefully evaluated. A fuller description of each type of hyperlipoproteinemia is presented elsewhere in this symposium (2).

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.